These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 26312707)

  • 1. Use of tumor necrosis factor alpha (TNF α) antagonists in a patient with psoriasis and Chagas disease.
    Navarrete-Dechent C; Majerson D; Torres M; Armijo D; Patel M; Menter A; de la Cruz C
    An Bras Dermatol; 2015; 90(3 Suppl 1):171-4. PubMed ID: 26312707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy comparison of ustekinumab between anti-tumor necrosis factor-α drug-naïve and anti-tumor necrosis factor-α drug-resistant Japanese psoriasis cases.
    Takahashi N; Noda S; Taniguchi T; Adachi M
    Int J Dermatol; 2015 Oct; 54(10):1194-8. PubMed ID: 26016819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down-regulation of the Th1, Th17, and Th22 pathways due to anti-TNF-α treatment in psoriasis.
    Luan L; Han S; Wang H; Liu X
    Int Immunopharmacol; 2015 Dec; 29(2):278-284. PubMed ID: 26585971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-TNF-α Drugs Differently Affect the TNFα-sTNFR System and Monocyte Subsets in Patients with Psoriasis.
    Gibellini L; De Biasi S; Bianchini E; Bartolomeo R; Fabiano A; Manfredini M; Ferrari F; Albertini G; Trenti T; Nasi M; Pinti M; Iannone A; Salvarani C; Cossarizza A; Pellacani G
    PLoS One; 2016; 11(12):e0167757. PubMed ID: 27936119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asymmetric dimethylarginine but not osteoprotegerin correlates with disease severity in patients with moderate-to-severe psoriasis undergoing anti-tumor necrosis factor-α therapy.
    Pina T; Genre F; Lopez-Mejias R; Armesto S; Ubilla B; Mijares V; Dierssen-Sotos T; Corrales A; Gonzalez-Lopez MA; Gonzalez-Vela MC; Blanco R; Hernández JL; Llorca J; Gonzalez-Gay MA
    J Dermatol; 2016 Apr; 43(4):389-94. PubMed ID: 26364678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient Adherence to Biologic Agents in Psoriasis.
    Hsu DY; Gniadecki R
    Dermatology; 2016; 232(3):326-33. PubMed ID: 27093295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-α level and the efficacy of TNF-inhibitor therapy in psoriasis.
    Kui R; Gál B; Gaál M; Kiss M; Kemény L; Gyulai R
    J Dermatol; 2016 Sep; 43(9):1018-23. PubMed ID: 26892625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of adalimumab after failure of other anti-TNFα agents for plaque-type psoriasis: clinician behavior in real life clinical practice.
    Esposito M; Prignano F; Rongioletti F; Hansel K; Bianchi L; Pescitelli L; Lazzeri L; Ricceri F; Mugheddu C; Bavetta M; Zangrilli A; Bianchi L; Bini V; Stingeni L
    J Dermatolog Treat; 2019 Aug; 30(5):441-445. PubMed ID: 30273075
    [No Abstract]   [Full Text] [Related]  

  • 9. Mechanistic target of rapamycin complex 1 is involved in psoriasis and regulated by anti-TNF-α treatment.
    Balato A; Lembo S; Ayala F; Balato N; Caiazzo G; Raimondo A; Di Caprio R; Monfrecola G
    Exp Dermatol; 2017 Apr; 26(4):325-327. PubMed ID: 27943462
    [No Abstract]   [Full Text] [Related]  

  • 10. Occurrence of a granulomatous mastitis and aseptic osteitis after anti-TNF therapy in a patient with pustular psoriasis.
    Garraud T; Barbarot S; Berthelot JM; Le Goff B
    Joint Bone Spine; 2016 Jan; 83(1):107-8. PubMed ID: 26054447
    [No Abstract]   [Full Text] [Related]  

  • 11. Treatment with TNF-α inhibitor rectifies M1 macrophage polarization from blood CD14+ monocytes in patients with psoriasis independent of STAT1 and IRF-1 activation.
    Lin SH; Chuang HY; Ho JC; Lee CH; Hsiao CC
    J Dermatol Sci; 2018 Sep; 91(3):276-284. PubMed ID: 29914850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The status of biologic therapies in the treatment of moderate to severe psoriasis.
    Menter A
    Cutis; 2009 Oct; 84(4 Suppl):14-24. PubMed ID: 19916298
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of adalimumab in patients with psoriasis previously treated with anti-tumour necrosis factor agents: subanalysis of BELIEVE.
    Ortonne JP; Chimenti S; Reich K; Gniadecki R; Sprøgel P; Unnebrink K; Kupper H; Goldblum O; Thaçi D
    J Eur Acad Dermatol Venereol; 2011 Sep; 25(9):1012-20. PubMed ID: 21214631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumour necrosis factor-α antagonists in patients with concurrent psoriasis and hepatitis B or hepatitis C: a retrospective analysis of 17 patients.
    Prignano F; Ricceri F; Pescitelli L; Zanieri F; Lotti T
    Br J Dermatol; 2011 Mar; 164(3):645-7. PubMed ID: 21375517
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eosinophilia--A rare possible adverse reaction during anti-tumor necrosis factor-alpha therapy for psoriasis.
    Chiriac A; Brzezinski P; Stolnicu S; Podoleanu C; Moldovan C; Molnar C; Taranu T
    J Dermatolog Treat; 2016; 27(2):110-3. PubMed ID: 26292921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biologic Therapy in Psoriasis (Part I): Efficacy and Safety of Tumor Necrosis Factor- α Inhibitors.
    Campanati A; Molinelli E; Brisigotti V; Offidani A
    Curr Pharm Biotechnol; 2017; 18(12):945-963. PubMed ID: 29424306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-TNF agents for the treatment of psoriasis.
    Kircik LH; Del Rosso JQ
    J Drugs Dermatol; 2009 Jun; 8(6):546-59. PubMed ID: 19537380
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Guillain-Barré syndrome in a patient on adalimumab for the treatment of psoriasis.
    Natividade NB; Felix PAO; Lerer C
    An Bras Dermatol; 2017; 92(5 Suppl 1):85-87. PubMed ID: 29267456
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?
    Langley RG
    J Eur Acad Dermatol Venereol; 2012 Mar; 26 Suppl 2():21-9. PubMed ID: 22356632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of severe psoriasis with TNF antagonists. Adalimumab, etanercept and infliximab.
    Mössner R; Reich K
    Curr Probl Dermatol; 2009; 38():107-136. PubMed ID: 19710553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.